Acadian Asset Management
RUBY

Acadian Asset Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Acadian Asset Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-179,676
Closed -$2K – 1974
2023
Q1 		$2K Sell
179,676
-1,097,520
-86% -$229K ﹤0.01% 1709
2022
Q4 		$222K Buy
1,277,196
+614,522
+93% +$168K ﹤0.01% 1259
2022
Q3 		$286K Buy
662,674
+257,327
+63% +$193K ﹤0.01% 1126
2022
Q2 		$345K Buy
+405,347
New +$680K ﹤0.01% 1078

Acadian Asset Management's RUBY Position: Q2 2023 in Review

Acadian Asset Management sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2023, closing a stake of 179,676 shares — an estimated $2K sold.

Acadian Asset Management first reported a position in RUBY in Q2 2022 and held it in 4 quarters. The position peaked at $345K in Q2 2022. 0 funds tracked by Wall St. Rank hold RUBY as of Q2 2023.

  • Acadian Asset Management reported no remaining Rubius Therapeutics, Inc position as of Q2 2023 after selling out during the quarter.
  • Acadian Asset Management sold 179,676 Rubius Therapeutics, Inc shares in Q2 2023, an estimated $2K.
  • Acadian Asset Management first reported a position in Rubius Therapeutics, Inc in Q2 2022 and held it in 4 quarters.
  • Acadian Asset Management's Rubius Therapeutics, Inc position peaked at $345K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2023.

Based on Acadian Asset Management's 13F filing for Q2 2023, filed 7 Aug 2023.